Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to 168.46%.

  • Standard Biotools' EBITDA Margin fell 475800.0% to 168.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.93%, marking a year-over-year increase of 301600.0%. This contributed to the annual value of 100.46% for FY2024, which is 284300.0% down from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' EBITDA Margin is 168.46%, which was down 475800.0% from 118.08% recorded in Q2 2025.
  • Standard Biotools' 5-year EBITDA Margin high stood at 29.42% for Q4 2021, and its period low was 205.37% during Q2 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 80.82% (2025), whereas its average is 96.05%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 4230900bps in 2021, then plummeted by -1497000bps in 2022.
  • Over the past 5 years, Standard Biotools' EBITDA Margin (Quarter) stood at 29.42% in 2021, then plummeted by -166bps to 78.13% in 2022, then grew by 3bps to 75.87% in 2023, then increased by 10bps to 68.24% in 2024, then crashed by -147bps to 168.46% in 2025.
  • Its EBITDA Margin stands at 168.46% for Q3 2025, versus 118.08% for Q2 2025 and 80.82% for Q1 2025.